Contact
Please use this form to send email to PR contact of this press release:
Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy
TO:
David Craig
Sarcomatrix Therapeutics Corp.
+1 415-246-3311